Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel

Clinical Pharmacology and Therapeutics

Volumn 105, Issue 1, 2019, Pages 219-228

  Itkonen, Matti K ^a   Tornio, Aleksi ^a   Lapatto Reiniluoto, Outi ^a   Neuvonen, Mikko ^a   Neuvonen, Pertti J ^a   Niemi, Mikko ^a   Backman, Janne T ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C8; DASABUVIR; RITONAVIR; ABT-333; ANTITHROMBOCYTIC AGENT; CYTOCHROME P450 3A INHIBITOR; SULFONAMIDE; URACIL;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; MAXIMUM CONCENTRATION; METABOLITE; NORMAL HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; THROMBOCYTE AGGREGATION INHIBITION; ADULT; BLOOD; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG POTENTIATION; FEMALE; MALE; YOUNG ADULT;

ADULT; CLOPIDOGREL; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A INHIBITORS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; RITONAVIR; SULFONAMIDES; URACIL; YOUNG ADULT;

EID: 85052407398     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.1099     Document Type: Article

References (45)

1. Messina, J.P., et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61, 77–87 (2015)
2. Deeks, E.D. Ombitasvir/paritaprevir/ritonavir plus dasabuvir: a review in chronic HCV genotype 1 infection. Drugs 75, 1027–1038 (2015)
3. US Food and Drug Administration. Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s) for Viekira Pak. (2014). Accessed 15 January 2018
4. Khatri, A., Trinh, R., Zhao, W., Podsadecki, T. & Menon, R. Drug-drug interaction between the direct-acting antiviral regimen of ombitasvir-paritaprevir-ritonavir plus dasabuvir and the HIV antiretroviral agent dolutegravir or abacavir plus lamivudine. Antimicrob. Agents Chemother. 60, 6244–6251 (2016)
5. Polepally, A.R., et al. Drug-drug interactions between the anti-hepatitis C virus 3D regimen of ombitasvir, paritaprevir/ritonavir, and dasabuvir and eight commonly used medications in healthy volunteers. Clin. Pharmacokinet. 55, 1003–1014 (2016)
6. Menon, R.M., et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J. Hepatol. 63, 20–29 (2015)
7. Shen, J., et al. Metabolism and disposition of hepatitis C polymerase inhibitor dasabuvir in humans. Drug Metab. Dispos. 44, 1139–1147 (2016)
8. Shebley, M., et al. Mechanisms and predictions of drug-drug interactions of the hepatitis C virus three direct-acting antiviral regimen: Paritaprevir/ritonavir, ombitasvir, and dasabuvir. Drug Metab. Dispos. 45, 755–764 (2017)
9. Shebley, M., Fu, W., Badri, P., Bow, D. & Fischer, V. Physiologically based pharmacokinetic modeling suggests limited drug-drug interaction between clopidogrel and dasabuvir. Clin. Pharmacol. Ther. 102, 679–687 (2017)
10. US Food and Drug Administration. Prescribing highlights for Viekira Pak. (2014). Accessed 15 January 2018
11. Backman, J.T., Filppula, A.M., Niemi, M. & Neuvonen, P.J. Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol. Rev. 68, 168–241 (2016)
12. King, J.R., Zha, J., Khatri, A., Dutta, S. & Menon, R.M. Clinical pharmacokinetics of dasabuvir. Clin. Pharmacokinet. 56, 1115–1124 (2017)
13. Tang, M., et al. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J. Pharmacol. Exp. Ther. 319, 1467–1476 (2006)
14. Tarkiainen, E.K., et al. Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans. Clin. Pharmacol. Ther. 97, 650–658 (2015)
15. Hagihara, K., et al. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab. Dispos. 37, 2145–2152 (2009)
16. Kahma, H., et al. Clopidogrel carboxylic acid glucuronidation is mediated mainly by UGT2B7, UGT2B4, and UGT2B17: implications for pharmacogenetics and drug-drug interactions. Drug Metab. Dispos. 46, 141–150 (2018)
17. Ji, J.Z., et al. Human UGT2B7 is the major isoform responsible for the glucuronidation of clopidogrel carboxylate. Biopharm. Drug Dispos. 39, 88–89 (2018)
18. Simon, T., et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363–375 (2009)
19. Gilard, M., et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J. Am. Coll. Cardiol. 51, 256–260 (2008)
20. Holmberg, M.T., Tornio, A., Neuvonen, M., Neuvonen, P.J., Backman, J.T. & Niemi, M. Grapefruit juice inhibits the metabolic activation of clopidogrel. Clin. Pharmacol. Ther. 95, 307–313 (2014)
21. Brayer, S.W. & Reddy, K.R. Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy. Expert Rev. Gastroenterol. Hepatol. 9, 547–558 (2015)
22. Tornio, A., et al. Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. Clin. Pharmacol. Ther. 96, 498–507 (2014)
23. Itkonen, M.K., Tornio, A., Neuvonen, M., Neuvonen, P.J., Niemi, M. & Backman, J.T. Clopidogrel markedly increases plasma concentrations of CYP2C8 substrate pioglitazone. Drug Metab. Dispos. 44, 1364–1371 (2016)
24. Kim, S.J., et al. Clarification of the mechanism of clopidogrel-mediated drug-drug interaction in a clinical cassette small-dose study and its prediction based on in vitro information. Drug Metab. Dispos. 44, 1622–1632 (2016)
25. Itkonen, M.K., et al. Clopidogrel but not prasugrel significantly inhibits the CYP2C8-mediated metabolism of montelukast in humans. Clin. Pharmacol. Ther. doi: 10.1002/cpt.947 (2017) [Epub ahead of print]
26. Arya, V., Zhao, P., Reynolds, K.S., Mishra, P. & Younis, I.R. Utilizing PBPK modeling to evaluate the potential of a significant drug-drug interaction between clopidogrel and dasabuvir: A scientific perspective. Clin. Pharmacol. Ther. 102, 578–580 (2017)
27. Itkonen, M.K., Tornio, A., Neuvonen, M., Neuvonen, P.J., Niemi, M. & Backman, J.T. Clopidogrel has no clinically meaningful effect on the pharmacokinetics of the organic anion transporting polypeptide 1B1 and cytochrome P450 3A4 substrate simvastatin. Drug Metab. Dispos. 43, 1655–1660 (2015)
28. Stark, J.E. Potential for a significant interaction between clopidogrel and dasabuvir. Clin. Infect. Dis. 61, 134–135 (2015)
29. Klibanov, O.M., Gale, S.E. & Santevecchi, B. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection. Ann. Pharmacother. 49, 566–581 (2015)
30. Jiang, X.L., Samant, S., Lesko, L.J. & Schmidt, S. Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin. Pharmacokinet. 54, 147–166 (2015)
31. Niemi, M., Backman, J.T., Neuvonen, M. & Neuvonen, P.J. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 46, 347–351 (2003)
32. Karonen, T., Filppula, A., Laitila, J., Niemi, M., Neuvonen, P.J. & Backman, J.T. Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. Clin. Pharmacol. Ther. 88, 223–230 (2010)
33. Jaakkola, T., Backman, J.T., Neuvonen, M. & Neuvonen, P.J. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin. Pharmacol. Ther. 77, 404–414 (2005)
34. Tornio, A., Niemi, M., Neuvonen, P.J. & Backman, J.T. Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Trends Pharmacol. Sci. 33, 312–322 (2012)
35. Hirvensalo, P., et al. Comprehensive pharmacogenomic study reveals an important role of UGT1A3 in montelukast pharmacokinetics. Clin. Pharmacol. Ther. doi: 10.1002/cpt.891 (2017) [Epub ahead of print]
36. Varma, M.V., et al. Transporter-mediated hepatic uptake plays an important role in the pharmacokinetics and drug-drug interactions of montelukast. Clin. Pharmacol. Ther. 101, 406–415 (2017)
37. US Food and Drug Administration. Center for Drug Evaluation and Research. Clinical Drug Interaction Studies — Study Design, Data Analysis, and Clinical Implications Guidance for Industry. (2017). Accessed 15 January 2018
38. Farid, N.A., et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin. Pharmacol. Ther. 81, 735–741 (2007)
39. Kirby, B.J., Collier, A.C., Kharasch, E.D., Whittington, D., Thummel, K.E. & Unadkat, J.D. Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir. Drug Metab. Dispos. 39, 1070–1078 (2011)
40. Aarnoutse, R.E., et al. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin. Pharmacol. Ther. 78, 664–674 (2005)
41. Kazui, M., et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab. Dispos. 38, 92–99 (2010)
42. Marsousi, N., et al. Impact of boosted antiretroviral therapy on the pharmacokinetics and efficacy of clopidogrel and prasugrel active metabolites. Clin. Pharmacokinet. doi: 10.1007/s40262-018-0637-6 (2018) [Epub ahead of print]
43. Metzger, N.L. & Momary, K.M. A patient with HIV and tuberculosis with diminished clopidogrel response. Int. J. Std. AIDS 25, 532–534 (2014)
44. Lordkipanidze, M., Pharand, C., Nguyen, T.A., Schampaert, E. & Diodati, J.G. Assessment of VerifyNow P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition. Ther. Drug Monit. 30, 372–378 (2008)
45. Jeong, Y.H., Bliden, K.P., Antonino, M.J., Park, K.S., Tantry, U.S. & Gurbel, P.A. Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies. Am. Heart J. 164, 35–42 (2012)